Advancing Vaccines
For Better Lives

Welcome to Valneva

We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We have leveraged our expertise and capabilities both to commercialize three vaccines, including the world’s first and only chikungunya vaccine, and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease and Zika.

Learn More

Check out our 2023 Annual Business Report

Learn More

Follow Us

✈️ Traveling can be stressful, from worries over a cancelled flight to lost baggage or even a foreign illness. It’s important to find ways to manage your #stress to fully enjoy your adventures.

What do you do to reduce your travel stress?

#Travel #TravelSeason

Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
https://valneva.com/press-release/valneva-appoints-dr-hanneke-schuitemaker-ph-d-as-chief-scientific-officer

Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine
https://ow.ly/G3gh50RCSAY

Load More